Immunservice

Executive Summary

Immunservice GmbH is a German biotechnology company specializing in interleukin-2 (IL-2) research and development. Founded in 2005 and headquartered in Berlin, the company offers ready-to-use cell culture media for specialized immune cells and is pioneering novel IL-2-based immunotherapies for oncology, virology, and other immune-related conditions. Immunservice operates across research tools, services, and therapeutic development, positioning itself as a niche player in the IL-2 space. With a focus on both commercial products and pipeline candidates, the company leverages its expertise to serve the growing demand for immune cell-based therapies. As a private firm, Immunservice has not disclosed funding rounds or valuation, limiting visibility into its financial trajectory. However, its established presence in the cell culture media market provides a steady revenue stream, while its therapeutic pipeline holds potential for future growth. The company's strategy appears to balance near-term product sales with long-term drug development, targeting indications with high unmet medical need.

Upcoming Catalysts (preview)

• TBDAdvancement of lead IL-2 immunotherapy candidate into clinical trials30% success
• TBDNew collaboration or licensing deal for proprietary IL-2 media or therapeutic50% success
• TBDExpansion of product portfolio with novel immune cell media formulations70% success